Propels in the Epidemiology of Functional GI Disorders

Advances in the epidemiology of functional gi disorders l.jpg
1 / 61
0
0
908 days ago, 213 views
PowerPoint PPT Presentation

Presentation Transcript

Slide 1

Progresses in the Epidemiology of Functional GI Disorders Dr Smita Halder Mount Sinai Hospital Toronto DDH Symposium March 20 th 2009

Slide 2

Outline FGID general diagram New advances

Slide 3

What is a Functional GI Disorder? Basic, unexplained clutters Irritable Bowel Syndrome Functional Dyspepsia Chronic stomach indications without biochemical or basic clarification Abdominal torment, bloating, sickness, inconsistent gut propensity, early satiety

Slide 4

How predominant in UK? IBD rates at age 30: 38 (per 10,000) for Crohn's ailment, 30 (per 10,000) for Ulcerative Colitis IBS rates: 826 (per 10,000) ~ 25 times more basic Ehlin et al, Gut 2003

Slide 5

Adapted from Talley, 1999 Prevalence of IBS (%) IBS predominance around the world?

Slide 6

Prevalence of IBS by age and sexual orientation in Olmsted County, MN Talley, 1999

Slide 7

Natural History Difficult to survey because of: Lack of forthcoming populace databases Indistinct nature of the phenotype Short term of follow up in past studies

Slide 8

Prevalence per 100 of FGID subgroups at two time focuses Halder et al, Gastro 2007

Slide 9

Symptom Transitions by and large: 33% had determination of side effects 33% had manifestation dependability 33% transitioned to another gathering Halder et al, Gastro 2007

Slide 10

consulters populace FGIDs – how enormous an issue? half of GI center workload 2% 7% 25% Majority of manifestations last >1 year

Slide 11

Burden of ailment (1) Quality of life is fundamentally  in IBS sufferers Halder et al, 2004 IBS sufferers Make more doctor visits than non-IBS Visit for non-GI grumblings with more recurrence Longstreth et al, 2003

Slide 12

Burden of sickness (2) Annual use for IBS, immediate and roundabout expenses: $30 billion in the US; £45.6 million in the UK £1000 spent/year/influenced persistent in the UK Expenditure for FD: £1 billion every year Cost to the NHS (remedies/indicative OGDs): £500 million every year Moayyedi et al, 2002

Slide 13

Rome III Process International arrangement framework Evolved from Manning criteria, 1978 Symptom groups anatomical areas Rome III distributed 2006 Aids institutionalization in clinical concentrates Rarely utilized as a part of non-research settings Robinson et al, Gut 2001

Slide 16

IBS Recurrent stomach agony or distress no less than 3 days for every month in the most recent 3 months that has at least two of the accompanying elements: Improved with defæcation Onset connected with an adjustment in recurrence Onset connected with an adjustment in shape Functional Dyspepsia at least one of: Bothersome postprandial totality Early satiation Epigastric torment Epigastric copying AND No proof of natural malady (counting at upper endoscopy) that is probably going to clarify the side effects Rome III Criteria

Slide 17

IBS Recurrent stomach torment or uneasiness no less than 3 days for each month in the most recent 3 months that has at least two of the accompanying components: Improved with defæcation Onset connected with an adjustment in recurrence Onset connected with an adjustment in frame Functional Dyspepsia at least one of: Bothersome postprandial completion Early satiation Epigastric torment Epigastric smoldering AND No confirmation of natural ailment (counting at upper endoscopy) that is probably going to clarify the side effects Rome III Criteria

Slide 18

Pathophysiology Brain-Gut Axis ENS/CNS collaboration Visceral touchiness Dysmotility of GI tract Biopsychosocial demonstrate

Slide 19

Psychosocial Factors Life stretch Psychological state Coping Social bolster Outcome QoL Daily capacity Health mind utilize Medications Work non-attendance IBS Symptoms Early life Genetic Environment Physiology Illness Behavior CNS PNS Brain-Gut Axis Intestinal Function Drossman, 2001

Slide 20

Potential Stressors

Slide 21

Potential Stressors

Slide 22

Potential Stressors

Slide 23

PhD Study Functional Gastrointestinal Symptoms: Risk elements for Consultation and Persistence

Slide 24

Hypothesis Psychosocial profile Consultation Clinical elements Persistence Infection

Slide 25

Baseline Follow-up FGID No FGID ? Onset Time Measure Risk Factors Measure Outcome Overall Study Design

Slide 26

Results Descriptive insights Consultation elements Persistence components

Slide 27

610 counseled GP with GI manifestations (12%) 66.6 % F 473 qualified 368 took an interest 105 declined 68.5% F Recruitment for GI ponder

Slide 28

Distribution of side effects %

Slide 29

Results Descriptive insights Consultation elements Persistence elements

Slide 30

4.00 3.50 3.00 2.65 2.50 Hazard Ratio* *Adjusted for age & sexual orientation 2.00 1.50 1.46 1.28 1.00 Highest level Sleep aggravation Highest level Illness conduct Females Hazard Ratios for Consulting: Multivariate Analysis

Slide 31

Results Descriptive insights Consultation variables Persistence elements

Slide 32

10 5 4.59 Odds Ratio* 3.08 3 2.45 *Adjusted for age & sex 1 GHQ at time of indications Symptoms for >3 months Symptom term >2 hours 0.1 Odds Ratios for Persistence: Multivariate Analysis

Slide 33

Odds Ratios for Persistence: Multivariate Analysis 10 5 Odds Ratio* 3 *Adjusted for age & sex 2.29 1 0.23 0.1 Adverse effect on day by day life Change in eating routine Gastroenteritis

Slide 34

Recent advances Genetics Brain imaging

Slide 35

Genetics of FGID Unlikely to be single hereditary element Probably an unpredictable communication between hereditary profile natural impacts phenotype all expansion powerlessness to sx onset

Slide 36

Familial bunching UK concentrate on: 100 IBS patients: 33% reported FHx IBS 100 coordinated controls: 2% reported FHx IBS Whorwell et al, Gut 1986 Mayo study: OR 2.3 [1.3-3.9] of having 1 st º relative with abdo torment/inside probs and reporting IBS/FD Locke et al, 2000

Slide 37

Twin Studies IBS twice as incessant in MZ twins cf DZ Morris-Yates et al, 1998; Levy et al 2001 Inherited pathophysiological systems or learned reaction? Offspring of IBS guardians visit healing facility more regularly than offspring of non-IBS guardians Levy et al, Am J Gastro 2000 Intergenerational transmission of sickness conduct

Slide 38

Individual qualities (1) Serotonin transporter quality: Functional polymorphism in SLC6A4 connected with looseness of the bowels in ladies with IBS LL genotype connected with reaction to alosetron (5HT 3 rec adversary) S allele connected with reaction to tegaserod Camilleri et al, Lancet 2000

Slide 39

Individual qualities (2) Cytokines: Interleukin-10 (mitigating) High-maker genotype more pervasive in controls than IBS Gonsalkorale et al, Gut 2003 TNF (star fiery) High-maker genotype more common in IBS than controls van der Veek et al, Am J Gastro 2005

Slide 40

Candidate Genes for IBS Receptors: Alpha-2A-adrenergic rec ( ADRA2A ) Alpha-2C-adrenergic rec ( ADRA2C ) 5-HT2A receptor ( 5-HT2A ) Neurotransmitter transporters: Serotonin transporter ( SLC6A4 ) Norepinephrine transporter ( NET ) Neurotransmitter digestion system: Fatty corrosive amide hydrolase ( FAAH ) Inflammatory markers: Interleukin-10 ( IL-10 ) Transforming development consider β 1 ( TGF-β1 ) Tumor putrefaction calculate alpha ( TNF-α ) Intracellular cell flagging: G protein β 3 subunit ( GNβ3 ) Ion channels: Sodium channel ( SCN5A )

Slide 41

Functional Dyspepsia Homozygous GN β 3 825CC bearer status essentially connected with upper-stomach sx Holtmann et al, Gastro 2004

Slide 42

GN β 3 C825T in lower FGID Olmsted County Study, Mayo Clinic 82 IBS-C; 94 IBS-D; 38 IBS-Alternating; 19 Abdo Pain 152 Controls GN β 3 C825T genotype dispersions comparable btwn cases/controls No affiliations found in lower FGIDs general Andresen et al, Gastro 2006

Slide 43

Limitations to hereditary studies Bias inborn in the study plan Poor factual examination Small specimen estimate Over elucidation of information

Slide 44

Advances in research instruments

Slide 45

Functional Brain Imaging Aids in exploring Brain-Gut associations CNS part in instinctive torment observation Positron Emission Tomography (PET) Functional Magnetic Resonance Imaging (fMRI) Magnetoencephalography (MEG)

Slide 46

PET scanner

Slide 47

Advantages Excellent spatial determination Can contemplate receptor locales Disadvantages Poor transient determination Radiation Expensive PET Radioisotope infused - cerebral blood stream measured

Slide 48

ACC Control ACC IBS Silverman, Gastro 1997

Slide 49

Control IBS Silverman, Gastro 1997

Slide 50

fMRI

Slide 51

Advantages Non-obtrusive Non-combined Good spatial determination Disadvantages Not continuous Response to torment not effortlessly mapped fMRI Neuronal action prompts to changes in blood stream, volume and oxygenation of Hb

Slide 52

fMRI

Slide 53

Activation by rectal torment amid stretch ACC: caudal front cingulate; PFC: right prefrontal cortex; pACC : perigenual foremost cingulate Morgan et al, Gut 2005

Slide 54

MEG

Slide 55

MEG Cortical neuromagnetic movement recognized Does not rely on upon metabolic changes Advantages Non-intrusive Good spatial determination Excellent worldly determination (ms) Disadvantages Expensive Not broadly accessible

Slide 56

MEG

Slide 57

IBS Abnormal example of ACC initiation amid agony discernment Amitriptyline diminishes torment related actuation in pACC amid push

Slide 58

Limitations to FGID Research Difficult phenotype Study settings: referral centers ? Outer legitimacy Study outlines: cross-sectional ? Causal variables or simultaneous components Bias: Recall Misclassification of cases Usually concentrate on one hazard area: mental/contamination/hereditary qualities

Slide 60

Thank you

Slide 61

Questions?

SPONSORS